Dataset Information

Biochemical network analysis of protein-protein interactions to monitor the course of T1 bladder cancer patients

ABSTRACT: Mass spectrometry-based personalized medicine was used to uncover key information in T1-stage bladder cancer (BC) patients and used as a tool to aid clinical decision making. The urinary proteome of patients with recurring versus non-recurring T1-stage BC were compared to uncover information for clinical decision making. Our results suggest the urinary myeloperoxidase to cubilin ratio as a new tool to address recurrence as well as dysregulation of the inflammatory and immune systems as drivers of a worsening disease course. Furthermore, dysregulation of neutrophil extracellular traps (NETs) is pinpointed as the leading way by which malignancy progress in BC showing the formation of an inflammatory microenvironment that facilitates immune cell-matrix cross-talk and promotes a state of chronic inflammation. We conclude that inflammation dysregulation is an important driver of BC recurrence and progression, and that anti-inflammatory or immune checkpoint therapies should be further explored in the treatment of patients with BC.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

DISEASE(S): Urinary Bladder Cancer

SUBMITTER: Hugo M. Santos

LAB HEAD: Hugo M. Santos

PROVIDER: PXD026784 | Pride | 2025-11-10

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Raw_pT1_BCa_Patients.zip	Other
	UP000005640_9606.fasta	Fasta
	UP000005640_9606_additional.fasta	Fasta
	andromeda_pT1_BCa_Patients.zip	Other
	mqpar_pT1_BCa_Patients.xml	Xml

Items per page:

1 - 5 of 7

Similar Datasets

Project description:We analysed, by last-generation high-resolution SNP arrays, Normal Karyotype (NK)-AML patients at diagnosis (Dx) and remission (R) phases, in order to determine the number of tumor-associated copy number abnormalities (CNAs) and copy neutral-loss of heterozygosity (CN-LOH) regions per patient and to identify possible recurring genomic abnormalities. The number of tumor-associated CNAs was detemined after comparison of 11 matched Dx/R samples using stringent conditions able to reduce the number of false positive CNAs. 8 additional unmatched Dx samples were included in the analysis of recurring CNAs and for detection of broad CN-LOH segments. With the exception of a single outlier case, a low number of CNAs per patient was detected (median value of 1 somatic loss or gain per patient). However, a high prevalence of CNAs (60-70% of the patients showed at least 1 tumor-associated gain or loss) and few recurring CNAs were observed, thus providing new hints towards identification of cooperating mutations. An extensive search of all CN-LOH regions > 1 Mb revealed only 3 broad regions (terminal 12Mb of 22q, terminal 27Mb of 1p and the whole chromosome 21) in three patients out of 19 (16%). CN-LOH of the whole chromosome 21 was responsible for homozygosity of a missense mutation (R80C) of RUNX1/AML1. Our study suggests that a relative submicroscopic copy number stability NK-AML genomes is associated with low recurrence of specific CNAs and CN-LOH in NK-AML patient population. Nineteen AML bone marrow samples were collected at the time of diagnosis (>90% blasts), defined as karyotypically-normal on the basis of standard metaphase cytogenetics (MC) and analysed by the Affymetrix SNP 6.0 arrays. In 11 of such cases (matched Dx) we obtained a bone marrow sample at the remission phase (matched R) of comparable high quality as evaluated by Contrast QC and MAPD values. In 8 cases (unmatched Dx) the corresponding R sample was not available or was not of comparable quality. As a reference set the publicly available data from 270 HapMap individuals were used.

Dataset Information

Biochemical network analysis of protein-protein interactions to monitor the course of T1 bladder cancer patients

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets